A randomized clinical trial investigating magnesium sulphate ability to reduce risk of
cerebral vasospasm after acute subarachnoid hemorrhage hence improving outcome particularly
in haptoglobin 2-2 patients who are highly susceptible for severe complications after
subarachnoid hemorrhage.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
General Committee of Teaching Hospitals and Institutes, Egypt
Collaborators:
Ain Shams University, Faculty of medicine, Egypt Health Insurance Organization, Egypt